Omnicell (OMCL) shares tumbled 9.81% in pre-market trading on Tuesday following the company's announcement of a reduced profit forecast for 2025, overshadowing its better-than-expected first-quarter results. The healthcare technology company's stock price movement reflects investors' concerns about its future earnings potential despite recent performance improvements.

For the first quarter of 2025, Omnicell reported total revenues of $270 million, marking a 10% increase from the same period last year and surpassing the IBES estimate of $260 million. The company's adjusted EBITDA reached $24 million, exceeding analyst expectations of $21.5 million. Adjusted net income stood at $12 million or $0.26 per diluted share, compared to the IBES estimate of $9.18 million. These results demonstrated Omnicell's ability to drive growth through its XT Amplify program, SaaS offerings, Expert Services, and Specialty Pharmacy Services.

However, the positive Q1 performance was overshadowed by Omnicell's revised full-year outlook. The company now projects non-GAAP earnings per share for fiscal year 2025 to be between $1.00 and $1.65, a significant reduction from previous estimates. This lowered profit forecast, coupled with a cautious Q2 outlook of $0.19 to $0.32 non-GAAP earnings per share on revenues between $270 million and $280 million, has sparked concerns among investors about Omnicell's growth trajectory and profitability in the face of ongoing macroeconomic challenges.